Zobrazeno 1 - 10
of 22
pro vyhledávání: '"G Karampekos"'
Autor:
N. Viazis, F. Almpani, A. Mountaki, K. Koustenis, C. Veretanos, A. Tsatsa, A. Trikola, E. Beka, K. Arvanitis, T. Georgiadi, G. Karampekos, E. Vienna, E. Archavlis, M. Mela, A. Christidou, C. Chantzievangelinou, K. Katopodi, V. Papastergiou, G. Mantzaris
Publikováno v:
ESGE Days 2022.
Autor:
S Ben-Horin, N Salomon, G Karampekos, N Viazis, A Lahat, B Ungar, R Eliakim, O Kriger-Sharabi, H Reiss-Mintz, H Yanai, I Dotan, E Zittan, N Maharshak, A Hirsch, M Weitman, G J Mantzaris, U Kopylov
Publikováno v:
Journal of Crohn's and Colitis. 17:i691-i691
Background The herbal extracts Curcumin and QingDai (QD, Indigo) were previously shown to be effective in mild-moderate and in moderate-severe ulcerative colitis (UC), respectively. We evaluated the efficacy and safety of a combination of curcumin-Qi
Autor:
Christos Pontas, A Christidou, Emmanouela Tsoukali, G Karampekos, Maria Gazouli, K Koustenis, Nikos Viazis, E. Archavlis, Gerassimos J. Mantzaris, Michail Galanopoulos, A Manolakis
Publikováno v:
Acta gastro-enterologica Belgica. 84(3)
Background-aim Intravenously administered biologicals are associated with a huge pressure to Infusion Units and increased cost. We aimed to assess the impact of switching infliximab to golimumab in ulcerative colitis (UC) patients in deep remission.
Publikováno v:
Journal of Crohn's and Colitis. 16:i413-i414
Background According to international guidelines mesalazine may have no place in the treatment of Crohn’s disease (CD). However, real-world studies have shown a defined, 5-ASA-dependent group of patients with CD whereas a large proportion of CD pat
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
M Vraka, S Panagopoulou, Gerassimos J. Mantzaris, H Beka, C Hatzievangelinou, K Mountaki, G Philippidis, C Veretanos, A Tsatsa, E. Archavlis, G Karampekos, A Christidou, A Manolakis, A Georgiadou, A Trikola, T Georgiadi, Nikos Viazis, F Albani
Publikováno v:
Journal of Crohn's and Colitis. 15:S366-S367
Background Anti-TNF agents, infliximab (IFX) and adalimumab (ADL) are first line treatment for moderate-to-severe Crohn’s disease (CD) and for preventing post-operative recurrence of CD (CD-POR) following right hemicolectomy (RH). However, a consid
Autor:
Gerassimos J. Mantzaris, Filippos Gkeros, E. Archavlis, G Filippidis, K Mountaki, M Mela, M Vraka, Emmanouela Tsoukali, G Karampekos, E Vienna, A Christidou, I Mitselos, K Koustenis, Dimitrios K. Christodoulou, Nikos Viazis, Christos Pontas
Publikováno v:
Journal of Crohn's and Colitis. 14:S484-S485
Background Small bowel capsule endoscopy (SBCE) is widely used for various indications in patients with established Crohn’s disease (CD). Our aim was to investigate whether SBCE can lead to changes in the therapeutic management of CD patients. Meth
Autor:
Christos Pontas, Christina Chatzievangelinou, Athanasios Tsigaridas, A Christidou, G Philippidis, Emmanouela Tsoukali, G Karampekos, Nikos Viazis, Gerassimos J. Mantzaris, Michail Galanopoulos
Publikováno v:
ESGE Days 2018 accepted abstracts.
Autor:
A Christidou, Georgios Theocharis, Olga Giouleme, M Tzouvala, E. Archavlis, Christos Pontas, G Filippidis, Emmanouela Tsoukali, G Karampekos, Nikos Viazis, Gerassimos J. Mantzaris, Michail Galanopoulos
Publikováno v:
Journal of Crohn's and Colitis. 13:S366-S367
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.